Vitry-sur-Seine, France
Vitry-sur-Seine, France

Aventis Pharma Limited, headquartered in Mumbai, is a part of Sanofi-Aventis group. Sanofi-Aventis and its 100% subsidiary Hoechst AG, are the major shareholders of Aventis Pharma Limited. Its manufacturing portfolio contains medicines for several therapeutic areas including cardiovascular, thrombotic, metabolic disorders, oncology, disorders of the central nervous system, internal medicine. Its primarily business is medicines in the dosage forms of liquid injectables, tablets, capsules, ointments, drops and syrup. In July 2003, company launched Lantus, the world's first and only once a day insulin. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Aventis Pharma | Date: 2016-11-04

The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.


Patent
Aventis Pharma | Date: 2014-08-07

The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.


Patent
Aventis Pharma | Date: 2014-12-18

The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.


Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.


The present invention relates to a novel crystalline ethyl acetate solvate form of cabazitaxel or 4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-7, 10-dimethoxy-9-oxo-11-taxen-13-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and process for preparing the same.


Patent
Aventis Pharma | Date: 2016-11-16

The present invention relates to the compound having the following formula (I):for its use as a medicament in the treatment of cancer in patients with hepatic impairment.


Patent
Aventis Pharma | Date: 2016-05-12

The present invention relates to the compound having the following formula (I):


Patent
Aventis Pharma | Date: 2014-12-18

The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.


The present invention relates to a novel crystalline ethyl acetate solvate form of cabazitaxel or 4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-7,10-dimethoxy-9-oxo-11-taxen-13-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and process for preparing the same.


Patent
Aventis Pharma | Date: 2015-09-03

The present disclosure relates to the compound having the following formula (I):

Loading Aventis Pharma collaborators
Loading Aventis Pharma collaborators